ExCellThera’s clinical program is currently focused on its most advanced technology, ECT-001 Cell Therapy.
Our vision is to make available for transplant, within 48 hours, our ECT-001 Cell Therapy cryo-preserved pre-expanded product for any patient in need.
Our Total Cell Therapy concept combines ECT-001 technology with modular add-on treatments to address any residual diseases using dendritic vaccines, CAR Stem Cells or small molecules that leverage surplus ECT-001 expanded product.
We also have a number of other programs in our R&D pipeline.
ExCellThera has several R&D programs in its pipeline, including the development of gene enhancer therapies, active degraders (PROTAC) and other targeted therapies.
ExCellThera is developing a pipeline of advanced cell therapies that are poised to challenge the current standard of care across various indications with unmet medical needs.
The company has a number of ongoing trials and R&D efforts at various stages of development. Link to Clinical Trials
ExCellThera’s ECT-001 technology renders more cord blood units avaliable to treat partients. Whereas only the largest 5% of units from a cord blood bank inventory can be used in treatments for adult patients (due to CD34 and TNC minimum dosage requirements), ECT-001 enables the potential use of over 90% of cord blood bank inventories.
In addition to providing a greater inventory of cord blood units available to select from for their patients, the ECT-001 technology also provides treating clinicians with greater flexibility in HLA matching and control over the administered T-cell dose